{
    "ticker": "ALIZY",
    "name": "Aliz\u00e9 Pharma 3",
    "description": "Aliz\u00e9 Pharma 3 is a biopharmaceutical company focused on the development of innovative therapies for metabolic diseases and rare diseases. Founded in 2017, the company is dedicated to addressing unmet medical needs through its proprietary drug development programs. Aliz\u00e9 Pharma 3 specializes in the research and development of treatments for conditions such as obesity, diabetes, and growth hormone deficiencies. The company\u2019s lead product candidate, AZP-3601, is designed to improve metabolic control in patients with obesity and related metabolic disorders. Through strategic partnerships and collaborations with leading research institutions, Aliz\u00e9 Pharma 3 aims to advance its pipeline of therapies through clinical trials and into the market. The company is committed to utilizing advanced biotechnology and research methodologies to ensure the efficacy and safety of its products. With a focus on innovation and patient-centric approaches, Aliz\u00e9 Pharma 3 is positioned to make significant contributions to the field of metabolic and endocrine disorders, striving to enhance the quality of life for patients worldwide.",
    "industry": [
        "Biopharmaceutical",
        "Healthcare"
    ],
    "headquarters": "Lyon, France",
    "founded": "2017",
    "website": "https://www.alize-pharma.com",
    "ceo": "Jean-Claude Poutrel",
    "social_media": {
        "twitter": "https://twitter.com/AlizePharma3",
        "linkedin": "https://www.linkedin.com/company/alize-pharma-3/"
    },
    "investor_relations": "https://www.alize-pharma.com/investors",
    "key_executives": [
        {
            "name": "Jean-Claude Poutrel",
            "position": "CEO"
        },
        {
            "name": "Pierre S. L. D. Duhamel",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "AZP-3601"
            ]
        }
    ],
    "seo": {
        "meta_title": "Aliz\u00e9 Pharma 3 | Innovating Metabolic Disease Therapies",
        "meta_description": "Explore Aliz\u00e9 Pharma 3, a biopharmaceutical company dedicated to developing innovative therapies for metabolic and rare diseases. Learn about our mission and products.",
        "keywords": [
            "Aliz\u00e9 Pharma 3",
            "Biopharmaceuticals",
            "Metabolic Diseases",
            "Obesity",
            "Diabetes",
            "Rare Diseases",
            "AZP-3601"
        ]
    },
    "faq": [
        {
            "question": "What is Aliz\u00e9 Pharma 3 focused on?",
            "answer": "Aliz\u00e9 Pharma 3 is focused on developing innovative therapies for metabolic and rare diseases."
        },
        {
            "question": "Who is the CEO of Aliz\u00e9 Pharma 3?",
            "answer": "Jean-Claude Poutrel is the CEO of Aliz\u00e9 Pharma 3."
        },
        {
            "question": "Where is Aliz\u00e9 Pharma 3 headquartered?",
            "answer": "Aliz\u00e9 Pharma 3 is headquartered in Lyon, France."
        },
        {
            "question": "What is the main product of Aliz\u00e9 Pharma 3?",
            "answer": "The main product candidate of Aliz\u00e9 Pharma 3 is AZP-3601, aimed at improving metabolic control."
        },
        {
            "question": "When was Aliz\u00e9 Pharma 3 founded?",
            "answer": "Aliz\u00e9 Pharma 3 was founded in 2017."
        }
    ],
    "competitors": [
        "PFE",
        "JNJ",
        "SNY",
        "RHHBY"
    ],
    "related_stocks": [
        "BMY",
        "MRNA",
        "AMGN",
        "GILD"
    ]
}